NCT00451048View on ClinicalTrials.gov

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

October 31, 2012

Conditions
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic SyndromesSecondary Myelodysplastic Syndromes
Interventions
DRUG

sunitinib malate

Given orally

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

N6A 4L6

London Regional Cancer Program, London

M4N 3M5

Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00451048 - Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter